Recurrent high grade glioma surgery with carmustine wafers implantation: a long-term nationwide retrospective study.
Carmustine wafer
Glioblastoma
High grade glioma
Prognostic factors
Recurrence
Survival
Journal
Journal of neuro-oncology
ISSN: 1573-7373
Titre abrégé: J Neurooncol
Pays: United States
ID NLM: 8309335
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
received:
08
02
2023
accepted:
10
03
2023
medline:
10
5
2023
pubmed:
30
3
2023
entrez:
29
3
2023
Statut:
ppublish
Résumé
Widespread use of carmustine wafers (CW) to treat high-grade gliomas (HGG) has been limited by uncertainties about its efficacy. To assess the outcome of patients after recurrent HGG surgery with CW implantation and, search for associated factors. We processed the French medico-administrative national database between 2008 and 2019 to retrieve ad hoc cases. Survival methods were implemented. 559 patients who had CW implantation after recurrent HGG resection at 41 different institutions between 2008 and 2019 were identified. 35.6% were female and, median age at HGG resection with CW implantation was 58.1 years, IQR [50-65.4]. 520 patients (93%) had died at data collection with a median age at death of 59.7 years, IQR [51.6-67.1]. Median overall survival (OS) was 1.1 years, OS of patients with recurrent HGG that underwent surgery with CW implantation is better in case of prolonged delay between the two resections and, for the patients who had RT and TMZ before and after CW implantation.
Identifiants
pubmed: 36991304
doi: 10.1007/s11060-023-04295-6
pii: 10.1007/s11060-023-04295-6
doi:
Substances chimiques
Carmustine
U68WG3173Y
Antineoplastic Agents, Alkylating
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
343-352Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996. https://doi.org/10.1056/NEJMoa043330
doi: 10.1056/NEJMoa043330
pubmed: 15758009
Azoulay M, Santos F, Shenouda G et al (2017) Benefit of re-operation and salvage therapies for recurrent glioblastoma multiforme: results from a single institution. J Neurooncol 132:419–426. https://doi.org/10.1007/s11060-017-2383-2
doi: 10.1007/s11060-017-2383-2
pubmed: 28374095
McBain C, Lawrie TA, Rogozińska E et al (2021) Treatment options for progression or recurrence of glioblastoma: a network meta-analysis. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD013579.pub2
doi: 10.1002/14651858.CD013579.pub2
pubmed: 34559423
pmcid: 8121043
Gavrielov-Yusim N, Friger M (2014) Use of administrative medical databases in population-based research. J Epidemiol Community Health 68:283–287. https://doi.org/10.1136/jech-2013-202744
doi: 10.1136/jech-2013-202744
pubmed: 24248997
Tuppin P, Rudant J, Constantinou P et al (2017) Value of a national administrative database to guide public decisions: from the système national d’information interrégimes de l’assurance maladie (SNIIRAM) to the système national des données de santé (SNDS) in france. Rev Epidemiol Sante Publique 65(Suppl 4):S149–S167. https://doi.org/10.1016/j.respe.2017.05.004
doi: 10.1016/j.respe.2017.05.004
pubmed: 28756037
Champeaux-Depond C, Weller J, Froelich S, Resche-Rigon M (2021) A nationwide population-based study on overall survival after meningioma surgery. Cancer Epidemiol 70:101875. https://doi.org/10.1016/j.canep.2020.101875
Constantinou P, Tuppin P, Fagot-Campagna A et al (2018) Two morbidity indices developed in a nationwide population permitted performant outcome-specific severity adjustment. J Clin Epidemiol 103:60–70. https://doi.org/10.1016/j.jclinepi.2018.07.003
doi: 10.1016/j.jclinepi.2018.07.003
pubmed: 30016643
Harrell FE Jr. (20015) Regression modelling strategies. Springer, New York
Therneau TM, Grambsch PM (2000) Modeling survival data: extending the Cox model. Springer, New York
doi: 10.1007/978-1-4757-3294-8
Schemper M, Smith TL (1996) A note on quantifying follow-up in studies of failure time. Control Clin Trials 17:343–346. https://doi.org/10.1016/0197-2456(96)00075-x
doi: 10.1016/0197-2456(96)00075-x
pubmed: 8889347
R Core Team (2014) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna
RStudio Team (2015) RStudio: Integrated development environment for R. RStudio Inc, Boston
Lang TA, Altman DG (2015) Basic statistical reporting for articles published in biomedical journals: The “Statistical Analyses and Methods in the Published Literature” or the SAMPL Guidelines. Int J Nurs Stud 52:5–9. https://doi.org/10.1016/j.ijnurstu.2014.09.006
doi: 10.1016/j.ijnurstu.2014.09.006
pubmed: 25441757
Nicholls SG, Quach P, Elm E von, et al (2015) The REporting of studies conducted using observational routinely-collected health data (RECORD) statement: methods for arriving at consensus and developing reporting guidelines. PLoS ONE 10:e0125620. https://doi.org/10.1371/journal.pone.0125620
Menei P, Metellus P, Parot-Schinkel E et al (2010) Biodegradable carmustine wafers (gliadel) alone or in combination with chemoradiotherapy: the French experience. Ann Surg Oncol 17:1740–1746. https://doi.org/10.1245/s10434-010-1081-5
doi: 10.1245/s10434-010-1081-5
pubmed: 20443147
Brem H, Piantadosi S, Burger PC et al (1995) Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The polymer-brain tumor treatment group. Lancet 345:1008–1012. https://doi.org/10.1016/s0140-6736(95)90755-6
doi: 10.1016/s0140-6736(95)90755-6
pubmed: 7723496
Chowdhary SA, Ryken T, Newton HB (2015) Survival outcomes and safety of carmustine wafers in the treatment of high-grade gliomas: a meta-analysis. J Neurooncol 122:367–382. https://doi.org/10.1007/s11060-015-1724-2
doi: 10.1007/s11060-015-1724-2
pubmed: 25630625
pmcid: 4368843
Attenello FJ, Mukherjee D, Datoo G et al (2008) Use of gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience. Ann Surg Oncol 15:2887–2893. https://doi.org/10.1245/s10434-008-0048-2
doi: 10.1245/s10434-008-0048-2
pubmed: 18636295
Price SJ, Whittle IR, Ashkan K et al (2012) NICE guidance on the use of carmustine wafers in high grade gliomas: a national study on variation in practice. Br J Neurosurg 26:331–335. https://doi.org/10.3109/02688697.2012.673651
doi: 10.3109/02688697.2012.673651
pubmed: 22482926
pmcid: 3432583
Hervey-Jumper SL, Berger MS (2014) Reoperation for recurrent high-grade glioma: a current perspective of the literature. Neurosurgery 75:491–499; discussion 498–499. https://doi.org/10.1227/NEU.0000000000000486
Bauchet L, Mathieu-Daudé H, Fabbro-Peray P et al (2010) Oncological patterns of care and outcome for 952 patients with newly diagnosed glioblastoma in 2004. Neuro Oncol 12:725–735. https://doi.org/10.1093/neuonc/noq030
doi: 10.1093/neuonc/noq030
pubmed: 20364023
pmcid: 2940657
Lonjon N, Bauchet L, Duffau H et al (2010) Second surgery for glioblastoma. A 4-year retrospective study conducted in both the montpellier and nice departments of neurosurgery. A literature review. Neurochirurgie 56:36–42. https://doi.org/10.1016/j.neuchi.2009.11.013
doi: 10.1016/j.neuchi.2009.11.013
pubmed: 20045159
Montemurro N, Perrini P, Blanco MO, Vannozzi R (2016) Second surgery for recurrent glioblastoma: a concise overview of the current literature. Clin Neurol Neurosurg 142:60–64. https://doi.org/10.1016/j.clineuro.2016.01.010
doi: 10.1016/j.clineuro.2016.01.010
pubmed: 26811867
Metellus P, Coulibaly B, Nanni I et al (2009) Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort. Cancer 115:4783–4794. https://doi.org/10.1002/cncr.24546
doi: 10.1002/cncr.24546
pubmed: 19637364
Kunwar S, Chang S, Westphal M et al (2010) Phase III randomized trial of CED of IL13-PE38QQR vs gliadel wafers for recurrent glioblastoma. Neuro Oncol 12:871–881. https://doi.org/10.1093/neuonc/nop054
doi: 10.1093/neuonc/nop054
pubmed: 20511192
pmcid: 2940677
Xiao Z-Z, Wang Z-F, Lan T, et al (2020) Carmustine as a supplementary therapeutic option for glioblastoma: a systematic review and meta-analysis. Front Neurol 11
Brem H, Mahaley MS, Vick NA et al (1991) Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. J Neurosurg 74:441–446. https://doi.org/10.3171/jns.1991.74.3.0441
doi: 10.3171/jns.1991.74.3.0441
pubmed: 1993909
Ameratunga M, Pavlakis N, Wheeler H, et al (2018) Anti‐angiogenic therapy for high‐grade glioma. Cochrane Database Syst Rev 2018:CD008218. https://doi.org/10.1002/14651858.CD008218.pub4
Ius T, Cesselli D, Isola M et al (2018) Combining clinical and molecular data to predict the benefits of carmustine wafers in newly diagnosed high-grade gliomas. Curr Treat Options Neurol 20:3. https://doi.org/10.1007/s11940-018-0489-2
doi: 10.1007/s11940-018-0489-2
pubmed: 29476361